IS7051A - Lyfjasamsetningar - Google Patents

Lyfjasamsetningar

Info

Publication number
IS7051A
IS7051A IS7051A IS7051A IS7051A IS 7051 A IS7051 A IS 7051A IS 7051 A IS7051 A IS 7051A IS 7051 A IS7051 A IS 7051A IS 7051 A IS7051 A IS 7051A
Authority
IS
Iceland
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
IS7051A
Other languages
English (en)
Inventor
Dixon John
Humphries Robert
Nicol Alexander
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7051A publication Critical patent/IS7051A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS7051A 2001-05-31 2003-11-26 Lyfjasamsetningar IS7051A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101932A SE0101932D0 (sv) 2001-05-31 2001-05-31 Pharmaceutical combinations
PCT/SE2002/001033 WO2002096428A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
IS7051A true IS7051A (is) 2003-11-26

Family

ID=20284321

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7051A IS7051A (is) 2001-05-31 2003-11-26 Lyfjasamsetningar

Country Status (24)

Country Link
US (2) US20040146498A1 (is)
EP (1) EP1397139A1 (is)
JP (1) JP2004532869A (is)
KR (1) KR20040003029A (is)
CN (1) CN100352442C (is)
AR (1) AR034343A1 (is)
AU (1) AU2002305952B2 (is)
BR (1) BR0210034A (is)
CA (1) CA2447648A1 (is)
CO (1) CO5550445A2 (is)
CZ (1) CZ20033246A3 (is)
EE (1) EE200300589A (is)
HU (1) HUP0400069A3 (is)
IL (1) IL158780A0 (is)
IS (1) IS7051A (is)
MX (1) MXPA03010761A (is)
NO (1) NO20035315D0 (is)
PL (1) PL366510A1 (is)
RU (1) RU2331422C2 (is)
SE (1) SE0101932D0 (is)
SK (1) SK14732003A3 (is)
TW (1) TWI232751B (is)
WO (1) WO2002096428A1 (is)
ZA (1) ZA200308780B (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
JP2004346067A (ja) * 2003-04-28 2004-12-09 Mitsubishi Pharma Corp 抗血栓薬の治療可能時間を延長するための薬剤
EP1685135B1 (en) 2003-10-21 2010-05-26 Inspire Pharmaceuticals, Inc. TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
CA2587026A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
JP2010508350A (ja) * 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
CA2780153A1 (en) * 2009-11-09 2011-05-12 Alexion Pharmaceuticals, Inc. Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
EP2507242A1 (en) * 2009-12-03 2012-10-10 AstraZeneca AB Co - crystals of a triazolo [4,5 - d]pyrimidine platelet aggregation inhibitor
EA026094B1 (ru) 2009-12-23 2017-03-31 Рациофарм Гмбх Твердая лекарственная форма тикагрелора
WO2011076401A1 (de) 2009-12-23 2011-06-30 Holger Schankin Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
JP2014516982A (ja) * 2011-06-01 2014-07-17 アストラゼネカ アクチボラグ 新規なチカグレロル共結晶
EA201501164A1 (ru) * 2013-05-29 2016-08-31 Рациофарм Гмбх Твердая фармацевтическая лекарственная форма
CN104277039B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途
WO2016116942A1 (en) * 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
RU2707959C2 (ru) * 2015-01-27 2019-12-03 Астразенека Аб Способ лечения или профилактики атеротромботических явлений у пациентов с инфарктом миокарда в анамнезе
CN106204544B (zh) * 2016-06-29 2019-04-05 南京中观软件技术有限公司 一种自动提取图像中标志点位置及轮廓的方法和系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
PL182680B1 (pl) * 1995-07-11 2002-02-28 Astrazeneca Ab Nowe inhibitory skupiania się płytek krwi
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
CN1346292A (zh) * 1999-03-11 2002-04-24 杜邦药品公司 凝血因子Xa抑制剂与阿司匹林、组织纤溶酶原激活物(TPA)、GPⅡb/Ⅲa拮抗剂、低分子量肝素或肝素联合用于治疗血栓形成
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations

Also Published As

Publication number Publication date
MXPA03010761A (es) 2004-03-02
ZA200308780B (en) 2005-02-11
CN1512885A (zh) 2004-07-14
US20060189584A1 (en) 2006-08-24
SK14732003A3 (sk) 2004-05-04
CA2447648A1 (en) 2002-12-05
CZ20033246A3 (cs) 2004-02-18
BR0210034A (pt) 2004-08-10
JP2004532869A (ja) 2004-10-28
PL366510A1 (en) 2005-02-07
RU2331422C2 (ru) 2008-08-20
RU2003133216A (ru) 2005-04-20
US20040146498A1 (en) 2004-07-29
HUP0400069A2 (hu) 2004-04-28
TWI232751B (en) 2005-05-21
EE200300589A (et) 2004-02-16
AU2002305952B2 (en) 2007-08-09
KR20040003029A (ko) 2004-01-07
EP1397139A1 (en) 2004-03-17
HUP0400069A3 (en) 2006-02-28
CN100352442C (zh) 2007-12-05
SE0101932D0 (sv) 2001-05-31
IL158780A0 (en) 2004-05-12
WO2002096428A1 (en) 2002-12-05
CO5550445A2 (es) 2005-08-31
NO20035315D0 (no) 2003-11-28
AR034343A1 (es) 2004-02-18

Similar Documents

Publication Publication Date Title
FI20011478A0 (fi) Farmaseuttinen koostumus
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
NO20033556L (no) Farmasöytiske formuleringer
ITMI20010748A0 (it) Composizioni farmaceutiche
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
NO20033384L (no) Farmasoytisk formulering
EE200300416A (et) Ravimvorm
FI20010780A0 (fi) Parannetut koostumukset
DK1524266T3 (da) Farmaceutisk sammensætning
EE200300589A (et) Ravimkoostised
BR0210619A (pt) composição
NO20035627D0 (no) Farmasöytisk formulering
NO20026123L (no) Farmasöytiske sammensetninger
FI20022128L (fi) Farmaseuttinen koostumus
NO20031095L (no) Farmasoytiske sammensetninger
DK1429753T3 (da) Farmaceutisk sammensætning omfattende gamma-butyrobetain
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
NO20044164L (no) Farmasoytiske sammensetninger
EE200300378A (et) Farmatseutiline kompositsioon
EE200200689A (et) Ravimkoostised
EP1413314A4 (en) MEDICAL COMPOSITIONS
FI5468U1 (fi) Farmaseuttinen koostumus
NO20041236L (no) Farmasoytisk formulering
SE0100847D0 (sv) Novel pharmaceutical composition